Navigation Links
EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease

WATERTOWN, Mass., July 7 /PRNewswire/ --

    WHAT:           EnVivo Pharmaceuticals to share results from its Ib/IIa
                    trial in Alzheimer's disease patients with its
                    nicotinic alpha-7 agonist EVP-6124.

    WHEN:           Wednesday, July 15, 2009.

    WHERE:          Alzheimer's Association 2009 International Conference
                    on Alzheimer's Disease (ICAD) in Vienna, Austria.

    WHO:            Dana Hilt, MD, senior vice president, clinical
                    development and chief medical officer, EnVivo

    ADDITIONAL:     EVP-6124 is EnVivo's novel alpha-7 nicotinic
                    acetylcholine receptor agonist currently in development
                    for Alzheimer's disease and cognitive dysfunction
                    associated with schizophrenia.  In this trial, safety
                    and effects on cognition of EVP-6124 were tested in
                    Alzheimer's patients already on long term treatment
                    with acetylcholine esterase inhibitors.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia). For more information about EnVivo, visit

SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries
2. Startech Environmental Advises Shareholders to Take No Action in Response to Friendly LRL Tender Offer
3. Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others
4. Ronald McDonald House Charities(R) (RMHC(R)) and McDonalds(R) Seek Inspiring Stories Through New Share.Give.Hope. Campaign
5. Shared Race, Social Group Seem to Help People Relate
6. Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th to Discuss Future Strategy
7. Sally Field Shares Her Osteoporosis Story on EmpowHer
8. Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders
9. AlphaRx Shareholder Update
10. Seroquels First- and Second-Line Patient Share Has Grown Since Last Years Analysis of Prescribing Trends in Bipolar Disorder
11. Arcadia Resources Responds to Share Price Volatility
Post Your Comments:
(Date:11/25/2015)... ... 2015 , ... Brillianteen, McGaw YMCA’s student-produced musical show, will ... Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for this final production ... been a treasured tradition for numerous families in the Evanston community. Over the ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing ... this disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Complex (TSC), as well as raising public awareness of the disorder while helping ... a third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to offer their patients the many benefits of the revolutionary BIOLASE WaterLase iPlus ... cutting and scraping tools traditionally used by a dentist in Gettysburg, PA ...
(Date:11/24/2015)... ... November 24, 2015 , ... ThirdLove, the fast-growing bra company ... early, offering 40% off select bras and underwear styles, now through Saturday, November ... fit technology and the latest fashion, quickly becoming the next generation of luxury ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Research and Markets ( ... Market - Global Forecast to 2020" report to ... accounting for 37.21% of the total market share in ... region is projected to growth at the highest ... attributed primarily to the fast growing water, industrial gas ...
(Date:11/24/2015)... DELHI , November 25, 2015 ... invoked due to repeated failure of IVF cycles. After ... Bhatia was totally dejected and had lost all hopes that she would be ... first Indian miracle child conceived after failure of over ... to abroad (UK) before they decided to take one last attempt ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
Breaking Medicine Technology: